Natesto Shortage: What Providers and Prescribers Need to Know in 2026

Prescribers managing hypogonadal patients on Natesto (testosterone nasal gel, CIII) increasingly report that patients are encountering difficulty filling their prescriptions. While there is no active FDA-declared shortage of Natesto, a combination of pharmacy stocking patterns, formulary restrictions, and cost barriers creates a practical availability problem for many patients. This guide summarizes what clinicians need to know and what they can do to help.

Current Availability Status: No FDA Shortage, but Structural Barriers Persist

As of 2026, Natesto is not listed on the FDA Drug Shortage Database. The manufacturer, Acerus Pharmaceuticals Corporation, has not announced any supply disruption. However, clinical experience and patient reports consistently indicate that Natesto is not reliably stocked at standard retail pharmacies in many markets.

The root causes are structural: Natesto is a brand-name-only Schedule III controlled substance with no approved generic equivalent. Its per-dispenser supply duration is approximately 10 days, requiring ~3 dispensers per month. Low prescription volume relative to other TRT formulations leads many pharmacies to deprioritize stocking it.

Formulary and Prior Authorization Challenges

A major contributor to access difficulty is insurance coverage. Natesto is not covered by most Medicare Part D plans. For commercial insurance, it frequently sits at Tier 3 or higher, often requiring prior authorization and sometimes step therapy — meaning the insurer may require the patient to try and fail another testosterone formulation before approving Natesto.

When writing prior authorization requests for Natesto, providers should document:

Confirmed diagnosis of hypogonadism with two morning serum testosterone measurements below 300 ng/dL

Clinical rationale for intranasal route over topical or injectable options (e.g., skin conditions, occupational transfer risk, fertility preservation, patient preference)

Any previous intolerance or inadequate response to other testosterone formulations

Absence of nasal contraindications (e.g., no chronic nasal disease, no recent nasal/sinus surgery, no deviated anterior nasal septum)

Key Prescribing Considerations for Natesto in 2026

Before prescribing or continuing Natesto, consider the following clinical points:

Fertility advantage. Unlike most testosterone formulations, Natesto's pulsatile pharmacokinetics (peak T at ~40 min, rapid clearance) appear to partially preserve HPG axis function. Phase 4 data suggest FSH and LH are less suppressed than with injectable testosterone. This makes Natesto an option for hypogonadal men who wish to preserve some degree of spermatogenesis.

Nasal contraindications. Natesto is not recommended for patients with chronic nasal conditions, deviated anterior nasal septum, mucosal inflammatory disorders, or nasal/sinus surgery within the past 6 months.

Allergic rhinitis. Symptomatic allergic rhinitis decreases Natesto absorption by 21–24%. Patients with active seasonal or allergic rhinitis may achieve subtherapeutic testosterone levels. Monitor serum T levels during allergy seasons.

Monitoring. Check serum testosterone starting 1 month after initiation. Target range is 300–1050 ng/dL. Discontinue if levels consistently exceed 1050 ng/dL. Monitor hematocrit, PSA, and blood pressure periodically.

Drug interactions. Monitor INR more frequently in patients on warfarin. Androgens may decrease insulin requirements in diabetics. Corticosteroid coadministration increases fluid retention risk.

Clinical Alternatives When Natesto Is Unavailable

If a patient cannot access Natesto, the following evidence-based alternatives deliver the same active hormone:

Testosterone cypionate IM injection — lowest cost, widely available generic, every 1–2 weeks; most suppressive of HPG axis.

Generic testosterone topical gel — widely available, good tolerability, once-daily; skin transfer precautions required.

Androderm patch — daily; mimics circadian T pattern; higher skin irritation rate.

Oral testosterone undecanoate (Jatenzo, Kyzatrex) — twice daily with meals; black box warning for BP elevation; no hepatotoxicity concerns with lymphatic absorption.

Clomiphene citrate (off-label) — for secondary hypogonadism; preserves fertility; oral, inexpensive generic.

How to Help Your Patients Access Natesto

Directing patients to medfinder can reduce treatment gaps. medfinder calls pharmacies on the patient's behalf to find which ones have Natesto in stock, saving the patient from time-consuming phone searches. You can also counsel patients on the Natesto Savings Card (commercially insured, co-pay as low as $0/month) and the Cash Option Program ($140 per prescription for uninsured patients) to address the cost barrier.

For more on supporting patients with prescription access, see our companion guide on how to help your patients find Natesto in stock.